Otter Bio
Otter Bio develops a new class of biologics that expands the discovery of cancer-relevant T cell antigens. They create fragmentable MHC proteins that preserve stable peptide MHC complexes, enabling identification of non-canonical epitopes that AI methods miss. The platform accelerates lead discovery, identifying up to five times more epitopes per mutation in about 24 hours and without clinical samples. Lead assets include a therapeutic peptide vaccine targeting KRAS G12D and G12V, with potential applications in immune monitoring and theragnostics. Otter Bio targets oncology therapeutics using stable peptide MHC complexes to expand the pool of starting points for next-generation cancer immunotherapies and libraries for broader discovery.
Otter Bio
Otter Bio develops a new class of biologics that expands the discovery of cancer-relevant T cell antigens. They create fragmentable MHC proteins that preserve stable peptide MHC complexes, enabling identification of non-canonical epitopes that AI methods miss. The platform accelerates lead discovery, identifying up to five times more epitopes per mutation in about 24 hours and without clinical samples. Lead assets include a therapeutic peptide vaccine targeting KRAS G12D and G12V, with potential applications in immune monitoring and theragnostics. Otter Bio targets oncology therapeutics using stable peptide MHC complexes to expand the pool of starting points for next-generation cancer immunotherapies and libraries for broader discovery.